Clinical evaluation of the cardiac toxicity of 4'-deoxy-doxorubicin.


4'-deoxy-doxorubicin, a new doxorubicin analog, was tested in 65 phase II patients with advanced malignancies. Cardiac toxicity evaluation was performed by means of electrocardiography (ECG), left ventricular systolic time intervals, echocardiography and radionuclide left ventricular ejection fraction. ECG abnormalities were observed in a lower percentage… (More)


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.